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Abstract
Serum hepcidin concentration is regulated by iron status, inflammation, erythropoiesis and
numerous other factors, but underlying processes are incompletely understood. We studied the
association of common and rare single nucleotide variants (SNVs) with serum hepcidin in one
Italian study and two large Dutch population-based studies. We genotyped common SNVs with
genome-wide association study (GWAS) arrays and subsequently performed imputation using
the 1000 Genomes reference panel. Cohort-specific GWAS were performed for log-transformed
serum hepcidin, adjusted for age and gender, and results were combined in a fixed-effects
meta-analysis (total N 6,096). Six top SNVs (p<5x10-6) were genotyped in 3,821 additional sam-
ples, but associations were not replicated. Furthermore, we meta-analyzed cohort-specific
exome array association results of rare SNVs with serum hepcidin that were available for two of
the three cohorts (total N 3,226), but no exome-wide significant signal (p<1.4x10-6) was identi-
fied. Gene-based meta-analyses revealed 19 genes that showed significant association with
hepcidin. Our results suggest the absence of common SNVs and rare exonic SNVs explaining a
large proportion of phenotypic variation in serum hepcidin. We recommend extension of our
study once additional substantial cohorts with hepcidin measurements, GWAS and/or exome
array data become available in order to increase power to identify variants that explain a smaller
proportion of hepcidin variation. In addition, we encourage follow-up of the potentially interesting
genes that resulted from the gene-based analysis of low-frequency and rare variants.
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Introduction
Iron is an essential trace element for fundamental metabolic processes in humans [1, 2]. Iron
deficiency limits hemoglobin synthesis and leads to anemia, whereas an excess of free iron is
toxic because it catalyzes the production of free radicals resulting in tissue damage [1, 2]. In
addition, iron imbalances have been associated with other diseases, e.g. diabetes mellitus [3, 4],
inflammation [5] and diseases of aging [6]. Hence, the iron balance in the human body is
tightly controlled, with the peptide hormone hepcidin as key regulator of systemic iron
homeostasis [7]. Hepcidin controls the absorption, storage and tissue distribution of iron by
binding to the cellular iron exporter ferroportin and inducing its internalization and degrada-
tion [8]. In this way, hepcidin regulates the uptake of dietary iron from the intestine and the
release of iron from macrophages involved in recycling of iron from senescent erythrocytes
[7].
In the last few years, several genome-wide association studies (GWAS) have revealed
genetic variants associated with iron status in the general population, including common vari-
ants in the hereditary hemochromatosis gene (HFE), transferrin gene (TF), transferrin recep-
tor and transferrin receptor 2 gene (TFRC, TFR2), solute carrier family 40 member 1 gene
(SLC40A1), and transmembrane serine protease 6 gene (TMPRSS6) [9–14]. On the contrary,
little is known about genetic determinants of hepcidin. Mutations in hepcidin antimicrobial
peptide (HAMP), the hepcidin encoding gene, lead to strongly decreased hepcidin levels and a
severe juvenile form of the iron storage disorder hereditary hemochromatosis (HH), but
HAMP mutations are very rare [15]. In addition, mutations in HFE, TFR2 and TMPRSS6 have
been related to hepcidin expression [15–20]. Furthermore, a single GWAS for serum hepcidin
has been published [21]. This study among 1,657 family members from the Val Borbera
genetic isolate was however underpowered to identify genome-wide significant associations
[21]. Here, we aimed to identify genetic determinants of serum hepcidin in a larger set of indi-
viduals from three large cohorts in order to unravel potential new pathways involved in hepci-
din regulation. We also studied the ratios of hepcidin to ferritin (hepcidin/ferritin) and
hepcidin to transferrin saturation (TS) (hepcidin/TS) given the known dependence of hepcidin
on stored iron and circulating iron, respectively [1, 2].
Materials and Methods
Study populations
We included three cohorts in our study: the Nijmegen Biomedical Study (NBS) (Nijmegen,
The Netherlands) [22], Prevention of REnal and Vascular ENd-stage Disease (PREVEND)
(Groningen, The Netherlands) [23] and Val Borbera (VB) (Milan, Italy) [24, 25] (S1 Table).
Blood samples for DNA isolation and biochemical measurements were obtained fasting in the
morning for PREVEND and VB, whereas blood samples were not fasting and sampled
throughout the day between 8 AM and 9 PM for NBS. All three studies were approved by
appropriate ethical committees (PREVEND: local medical ethics committee; NBS: Radboud
university medical center Institutional Review Board; VB: institutional review boards of San
Raffaele Hospital in Milan and by the Regione Piemonte ethical committee), and all partici-
pants gave informed consent.
Laboratory methods
Serum hepcidin concentration was measured with a competitive enzyme-linked immunosor-
bent assay in NBS and PREVEND samples as described before [26, 27]. In VB samples, serum
hepcidin was measured with a validated mass spectrometry based method as described before
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[21]. Serum ferritin, iron, transferrin, TS and C-reactive protein (CRP) were measured accord-
ing to standard methods. See S2 Table for details. Phenotype information (median and 5th-95th
percentiles) is presented in S3 Table.
Genotyping
All three cohorts were genotyped with a GWAS-chip: PREVEND with the Illumina Cyto
SNP12 v2, NBS with the Illumina HumanHap370CNV-Duo BeadChip, and VB with the Illu-
mina HumanHap370CNV-Quad BeadChip v3. Standard quality checks were performed (fil-
ters for sample yield, SNV yield, MAF and HWE) and data were imputed to increase SNV
density and harmonize SNV data over the cohorts using 1000 Genomes phase 1 version 3 as
reference panel (S4 Table). Quality control also included evaluation of population stratifica-
tion. For PREVEND, principal component analysis was used and samples with a Z-score>3
for the first five principal components were excluded. For NBS, Structure analysis was used
and samples with less than 89% Caucasian ancestry were excluded. For VB, principal compo-
nents were used in the analysis to adjust for potential population stratification.
Genome-wide association analysis
GWAS were performed in each cohort separately according to a set protocol. Analyses were
performed for all individuals (PREVEND: N = 2,902; NBS: N = 1,819; VB: N = 1,480), and also
for a subset (PREVEND: N = 2,695; NBS: N = 1,495; VB: N = 1,206) from which individuals
with ferritin <30 ng/mL and CRP10 mg/L were excluded as to remove individuals with iron
deficiency and clinical inflammation [28], respectively, since both of these acquired conditions
are associated with altered iron stores and altered iron transport [1,2]. Hepcidin and the ratios
hepcidin/ferritin and hepcidin/TS were log-transformed and thereafter adjusted for age and
squared age, independent determinants of serum hepcidin [21, 26], separately for males and
females. For NBS, blood sampling was performed throughout the day, and therefore time of
blood sampling was used as an additional covariate to account for the circadian rhythm of hep-
cidin [29] (three categories: before 12 PM, between 12 and 5 PM and after 5 PM in line with
previously reported hepcidin concentration patterns throughout the day [30, 31]). Sex-specific
residuals were calculated and merged into one variable. Outliers, defined as values that differed
more than four times the SD from the mean, were excluded (Nmax = 12). For PREVEND and
NBS, the association between the single nucleotide variants and the trait was tested by linear
regression using genotype probabilities and an additive model on the standardized residuals
(Z score). For VB, a linear mixed model was used with a kinship (relatedness) matrix to
account for the relatedness in this sample [32], also using genotype probabilities and an addi-
tive model on the standardized residuals (Z score).
Meta-analysis
The GWAS results from the three cohorts were combined in a fixed-effects meta-analysis
using the software package METAL [33]. The standard-error based approach was used, which
weighs effect size estimates using the inverse of the corresponding standard errors. Variants
with a minor allele frequency<1% and a poor imputation quality (SNPtest info value or
MACH RSQR <0.4) were excluded prior to the meta-analysis. To adjust for potential residual
population stratification, we applied genomic control correction to the individual cohorts
(genomic inflation factors [lambdas] for GWAS results ranged from 0.989 to 1.015 in the three
cohorts, indicating a negligible amount of population stratification) [34]. A heterogeneity anal-
ysis was performed to test whether observed effect sizes were homogeneous across cohorts.
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Resulting betas express the change in log-transformed hepcidin (or the ratios) that can be
attributed to each copy of the effect allele (additive model).
Replication
Our financial budget allowed us to genotype six SNVs with single SNP assays in all additional
independent samples that were available for PREVEND (N = 2,876) and NBS (N = 1018). For
the VB cohort, no additional samples were available. Single-SNP genotyping in PREVEND
samples was performed by KBiosciences (KBiosciences, Herts, UK) utilizing the SNPline sys-
tem. Single-SNP genotyping in NBS samples was carried out by deCODE Genetics using the
Centaurus (Nanogen) platform [35]. The quality of each Centaurus SNP assay was evaluated
by genotyping HapMap CEU samples with each assay and comparing the results with the Hap-
Map data. All assays were reliable, as the mismatch rates were all<0.5%. Association analyses
were performed using the same strategy as for the discovery meta-GWAS: cohort-specific asso-
ciation analyses and subsequent combination of summary statistics in a fixed-effects meta-
analysis. We also meta-analyzed these replication results together with the discovery meta-
analysis results.
Gene-based analysis
We performed gene-based analysis on SNV association P-values from the meta-analysis of dis-
covery samples using VEGAS2 [36, 37]. Statistical significance of gene-based analysis results
was based on Bonferroni correction of testing ~21,000 genes (P<2.4x10-6).
DEPICT
Data-driven Expression Prioritized Integration for Complex Traits (DEPICT, “v1 beta version
rel194 for 1KG imputed”) was applied to the meta-GWAS discovery results to highlight
enriched pathways and identify tissues/cell types in which genes from associated loci are highly
expressed [38]. Meta-GWAS association results with p<1x10-5 were pruned using PLINK
v1.09 to obtain independent SNVs (‘—clump-kb 500—clump-p1 1e-05—clump-r2 0.1’) using
the CEU (Utah Residents [CEPH] with Northern and Western Ancestry), GBR (British in
England and Scotland) and TSI (Toscani in Italy) 1000 Genomes populations as reference to
obtain the correlation structure of the SNVs. These pruned data were used as input for the
DEPICT analysis using default settings. Details of the DEPICT analysis can be found in S1
File.
Exome array association analysis
Exome array data measured with the Illumina HumanExome BeadChip were available for
both NBS and VB. Genotype data were called with the default genotype caller in Genome Stu-
dio and uncalled genotypes were recalled using the zCall algorithm, which is specifically
designed for calling rare variants [39]. Filters for sample yield, SNV yield, and HWE were
applied, resulting in a total N of1,753 for NBS and 1,473 for VB after QC (S5 Table). Phenotype
information for the exome array samples is given in S6 Table. Analyses were performed using
the phenotypes as described under ‘Genome-wide association analysis’. Single variant analyses
were performed to obtain cohort specific score statistics and their covariance matrix (RvTests
software version 20150629 [http://zhanxw.github.io/rvtests/]). For VB, a kinship matrix was
included in the analyses to account for relatedness. Cohort specific results were meta-analyzed
in RareMETAL software version 4.13.8 (http://genome.sph.umich.edu/wiki/RAREMETAL_
Documentation) on single variant level and in a gene-level test [sequence kernel association
Genetic Variation and Serum Hepcidin
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test (SKAT)] [40]; only non-synonymous, splice site and stop variants with a MAF5% were
included in the gene-level test.
Single variant results were filtered for a pooled minor allele frequency between 0.001 and
0.05 to prevent repeated analysis of the common variants and at the same time reduce the
number of statistical tests. The lower bound frequency of 0.001 corresponds to a minor allele
count of 6 for the whole cohort with exome array data (N up to 3,226), and 5 for the subset (N
up to 2,623).
SKAT meta-analysis in RareMETAL presents an exact and approximate p-value in the output.
We used the exact test called “Davies”, which computes the p-value by inverting the characteristic
function of the mixture chisq, which is often used as the default in statistical analysis packages.
The statistical significance of single variant and gene-based exome array meta-analysis
results was based on Bonferroni correction of testing ~37,000 variants (p< 1.4 x10-6) and
~14,000 genes (p< 3.6 x10-6), respectively.
Power calculation
Power analysis were performed using GWAPower Detection V1.1 [41]. Effective sample size of
the VB cohort to take into account relatedness was determined using Greffa software [42] based
on a pairwise kinship coefficient<0.0625, resulting in an effective sample size of N = 714.
Results
Meta-analysis of GWAS (total N 6,096) revealed two loci that were genome-wide significantly
associated (p<5x10-8) with serum hepcidin (Table 1): one on chromosome 10 in all individuals
(rs118031191, nearest gene FOXI2) and one on chromosome 2 in the subset (four SNVs in
EML6 with lead SNV rs354202). S1 and S2 Figs show Manhattan and QQ plots for the meta-
GWAS for hepcidin in all individuals and in the subset, respectively. S3 and S4 Figs show the
regional association plots for rs118031191 and rs354202, respectively. We also performed con-
ditional analysis for the chromosome 2 locus in NBS data by adjusting for lead SNV rs354202
to investigate whether the additional signals at this locus identified in the discovery analysis
were independent from rs354202. Associations disappeared upon adjustment for this SNV,
revealing that all other signals at the chromosome 2 locus were driven by rs354202 (S5 and S6
Figs). No novel significant loci were found for the ratios hepcidin/ferritin and hepcidin/TS
(Manhattan and QQ plots in S7–S10 Figs), but previously identified associations were con-
firmed: for the hepcidin/ferritin ratio we observed genome-wide significant associations with
variation in HFE and TMPRSS6 (S7 Table), and for hepcidin/TS with variation in TMPRSS6,
but not with HFE (S8 Table).
Gene-based analysis (S9 Table for results with p<1x10-2) did only show significant associa-
tion for hepcidin/ferritin with HFE (all p = 7.2x10-7; subset p = 8.2x10-7). No significant
enriched gene sets or tissues were identified for all traits (S10 and S11 Tables).
Six SNVs were brought forward to replication: rs354202, rs118031191, rs56281245 and
rs12289793 were selected based on p<1x10-6 for association with hepcidin, and rs1835473 and
rs12441903 were additionally selected based on hepcidin association p-values close to 1x10-6,
location inside genes, and MAF >10%. All SNVs selected for replication had a non-significant
p-value for the heterogeneity test (p>0.05). Replication analysis (N 3,821) revealed no signifi-
cant associations at p = 0.05 (Table 2).
Meta-analysis on single variant level of exome array variants (total N 3,226) revealed no sig-
nificantly associated SNVs for hepcidin (S12 Table presents results with p<1x10-3). The most
significant signal was located in PCDHB1 (exm485355, p = 4.4x10-5) for all individuals and in
PTPN13 for the subset (exm411306, p = 2.1x10-5). Also for hepcidin/TS no significant signals
Genetic Variation and Serum Hepcidin
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were observed, but for hepcidin/ferritin we identified two signals that reached exome-wide sig-
nificance: exm470499 in WDR36 (all; p = 9.9x10-7) and exm162358 in MTR (subset;
p = 2.7x10-8); variants close to and in these genes have previously been associated with allergy
[43] and homocysteine levels [44], respectively. Gene-based meta-analyses (S13 Table)
revealed eight genes that showed significant association with hepcidin in all individuals, and
11 in the subset, but none of these genes overlapped. For hepcidin/ferritin, 10 and nine genes
showed significant association in all individuals and in the subset, respectively, with one over-
lapping gene, namely PAPSS1. This gene was described as a candidate gene for telomere length
based on a GWAS [45]. Previously, elevated iron phenotype was associated with shortened
telomeres [46], indicating a potential link between this gene and systemic iron homeostasis.
For hepcidin/TS, nine and 16 genes were significant in all individuals and in the subset, respec-
tively, but none overlapped.
Table 2. Results of the replication analyses and discovery and replication combined.
Replication Discovery + Replication
SNV Population A1* A2 Freq A1
PREVEND
Freq A1
NBS
Beta SE p Direction# N Beta SE p Direction† N
rs12289793 All A G 0.78 0.72 0.02 0.03 0.38 ++ 3770 0.06 0.02 7.01E-
04
+++ 9866
Subset A G 0.78 0.74 0.03 0.03 0.31 ++ 3072 0.09 0.02 1.49E-
05
+++ 8123
rs1835473 All A G 0.68 0.70 0.03 0.02 0.32 ++ 3754 0.07 0.02 1.48E-
05
+++ 9850
Subset A G 0.68 0.70 0.02 0.03 0.49 +- 3059 0.05 0.02 2.27E-
03
++- 8110
rs56281245 All T C 0.95 0.95 0.06 0.05 0.24 ++ 3798 0.12 0.04 8.40E-
04
+++ 9894
Subset T C 0.95 0.96 0.04 0.06 0.56 ++ 3092 0.16 0.04 3.83E-
05
+++ 8143
rs118031191 All A G 0.03 0.03 0.00 0.07 1.00 -+ 3821 -0.18 0.05 9.12E-
05
- -+ 9917
Subset A G 0.03 0.03 0.00 0.07 0.96 -+ 3115 -0.16 0.05 2.60E-
03
- -+ 8166
rs12441903 All A G 0.89 0.87 -0.04 0.04 0.33 - - 3816 -0.10 0.02 3.13E-
05
- - - 9912
Subset A G 0.89 0.87 -0.03 0.04 0.41 - - 3108 -0.10 0.03 6.29E-
05
- - - 8159
rs354202‡ All A G 0.89 0.89 -0.03 0.04 0.39 +- 3810 -0.11 0.02 3.32E-
06
-+- 9906
Subset A G 0.90 0.89 0.00 0.04 0.92 -+ 3109 -0.12 0.03 9.24E-
06
—+ 8160
A indicates allele; BP, base pair position; Freq, frequency; N, number; SE, standard error; SNV, single nucleotide variant. Association analysis were
performed using the same strategy as for the discover meta-GWAS: cohort-specific association analyses and subsequent combination of summary
statistics in a meta-analysis using only replication samples (Replication) and the discovery meta-analysis and replication samples combined (Discovery
+ Replication). The betas express the change in log-transformed hepcidin that can be attributed to each copy of allele 1 (additive model). HWE p-values in
PREVEND and NBS, respectively, were for rs12289793: p = 0.71 and 0.89; for rs1835473 p = 0.001 and 0.90; for rs56281245 p = 0.12 and 0.90; for
rs118031191 p = 0.04 and 0.29; for rs12441903 p = 0.04 and 0.95; and for rs354202 p = 0.051 and 0.45.
*A1 is the effect allele in the association analysis.
#Order of direction: NBS, PREVEND.
†Order of direction: discovery meta-analysis, NBS, PREVEND.
‡In PREVEND, a proxy of rs354202 was measured (rs76949049; r2 with rs354202 = 1).
doi:10.1371/journal.pone.0166628.t002
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Discussion
This is the first meta-analysis of GWAS and exome array results for serum hepcidin. The fact
that our meta-analysis revealed no SNVs that were significantly associated with serum hepci-
din suggests that there are no common, low-frequency or rare variants that explain a large pro-
portion of phenotypic variation in serum hepcidin. Indeed, with our meta-analysis of
common variants (N 6,096, effective sample size N 5,331) we had 80.0% and 97.8% chance of
detecting (at alpha 5x10-8) a SNV that explains 0.71% and 1.00% of hepcidin variance, respec-
tively. For our meta-analysis of exome array results (N 3,226, effective N 2,467) we had 80.0%
and 99.2% chance of detecting (at alpha 1.4x10-6) a SNV explaining 1.22% and 2.00% of hepci-
din variance, respectively. For comparison, the well-known iron-related SNVs rs1800562 in
HFE and rs855791 in TMPRSS6 explain ~1% of serum iron variation. In addition, (narrow-
sense) heritability of hepcidin was previously estimated to be 9.8% but non-significant
(p>0.05) in the VB population and genome-wide SNP explained variance adjusted for age and
gender was estimated at ~37% (SE~20%) in the NBS (data not shown). Overall, this suggests
that a large part of hepcidin variability is caused by variation in environmental factors, e.g.
inflammation, body-mass index and body iron stores (dietary intake and blood losses).
Serum hepcidin was not associated with common variants in HFE and TMPRSS6, as we
have previously shown in independent studies both in the VB and NBS population [21, 47].
Now, we have also shown that low-frequency or rare variants in these genes do not seem to
contribute, neither at single variant level nor at gene level. We confirmed previously reported
associations for rs1800562 in HFE and rs855791 in TMPRSS6 with the ratio hepcidin/ferritin
for the VB and NBS population [21, 47]. As expected, we further substantiated these associa-
tions here and found an even stronger signal. The association signal of the ratio hepcidin/TS
with common variants in HFE and TMPRSS6 was less strong. Of note, the association of
rs1800562 in HFE with the ratio hepcidin/TS, previously found in the NBS [47], disappeared
upon meta-analysis of results of NBS, PREVEND and VB in all individuals (p = 0.13), but still
showed a weak signal in the subset (p = 3.7Ex10-4). Also rs855791 in TMPRSS6 showed a stron-
ger signal for association with the ratio hepcidin/TS in the subset compared to analysis based
on all individuals. The stronger signal of rs1800562 and rs855791 with the ratio hepcidin/ferri-
tin compared to the ratio hepcidin/TS indicates that these SNVs have a larger influence on
hepcidin response to body iron stores than on hepcidin response to circulating iron.
There are several reasons that can cause failure of identifying a true association signal [48,
49], e.g. issues of heterogeneity between studies, such as variability in outcome measurement
or statistical analysis, or bias due to population stratification. We took those issues into
account by using a set analysis protocol for cohort-specific analysis, testing for heterogeneity
for the top hits, and adjusting for population stratification in each cohort next to application of
genomic control adjustment. Two different hepcidin assays were applied in this study, but cor-
relation between these assays was high as measured in international round robins (sample
send-out studies) for hepcidin assay harmonization (DWS and DG, unpublished findings). In
addition, we prevented bias in SNV-hepcidin associations due to differences in hepcidin assays
by first performing cohort-specific GWAS and thereafter combining results in a meta-analysis.
However, it is important to realize that there are additional reasons that may have masked true
association results in our study, e.g. residual confounding due to population stratification,
presence of comorbidities that associate with serum hepcidin levels, incomplete adjustment
for relatedness in the VB cohort, genetic or environmental interactions [48, 49], or high bio-
logical variation in serum hepcidin levels [29, 30, 31, 50].
In conclusion, our results indicate that there are no common SNVs that explain more than
1% and no low-frequency and rare SNVs that explain more than 2% of phenotypic hepcidin
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variation. We recommend extension of our study once additional substantial cohorts with
hepcidin measurements, GWAS and/or exome array data become available in order to
increase power to identify variants that explain a smaller proportion of hepcidin variation. In
addition, we encourage follow-up of the potentially interesting genes that resulted from the
gene-based analysis of low-frequency and rare variants with candidate gene, fine mapping and
functional studies to increase the level of evidence for association and obtain insight into the
underlying mechanism of action.
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